Vivos Therapeutics (VVOS) Cash from Investing Activities (2020 - 2026)
Vivos Therapeutics (VVOS) reported Cash from Investing Activities of -$18000.0 for Q1 2026, up 85.25% year-over-year from -$9716.8 in Q1 2025, and up 98.86% on a QoQ basis from -$1.6 million in Q4 2025.
Vivos Therapeutics (VVOS) has 7 years of Cash from Investing Activities data on file, last reported at -$18000.0 in Q1 2026.
- Quarterly Cash from Investing Activities rose 85.25% year-over-year to -$18000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$7.4 million (down 1276.99% YoY) and the FY2025 annual result came in at -$7.5 million, down 1225.0% from the prior year.
- Cash from Investing Activities rose to -$18000.0 in Q1 2026 per VVOS's latest filing, from -$1.6 million in the prior quarter.
- Across five years, Cash from Investing Activities topped out at $83000.0 in Q3 2025 and bottomed at -$5.9 million in Q2 2025.
- The 5-year median for Cash from Investing Activities is -$165000.0 (2023), against an average of -$581705.9.
- Peak annual rise in Cash from Investing Activities reached 143.23% in 2025, while the deepest fall reached 9743.33% in 2025.
- Tracing VVOS's Cash from Investing Activities over 5 years: stood at -$200000.0 in 2022, then gained by 17.5% to -$165000.0 in 2023, then changed by 0.0% to -$165000.0 in 2024, then slumped by 858.18% to -$1.6 million in 2025, then soared by 98.86% to -$18000.0 in 2026.
- Per Business Quant, the three latest VVOS Cash from Investing Activities figures stand at -$18000.0 (Q1 2026), -$1.6 million (Q4 2025), and $83000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | -20.32 Bn |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | -185.00 Mn |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | -816.00 Mn |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | -591.00 Mn |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | -92.80 Mn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | -475.32 Mn |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | -298.50 Mn |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | -2.50 Bn |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | -217.20 Mn |
| 10 | Vivos Therapeutics | 9.87 Mn | 7.64 Mn | 3.06 Mn | -18,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -18,000.00 |
| Mar 31, 2026 | -18,000.00 |
| Dec 31, 2025 | -1.58 Mn |
| Dec 31, 2025 | -1.58 Mn |
| Sep 30, 2025 | 83,000.00 |
| Sep 30, 2025 | 83,000.00 |
| Jun 30, 2025 | -5.91 Mn |
| Jun 30, 2025 | -5.91 Mn |
| Mar 31, 2025 | -122,000.00 |
| Mar 31, 2025 | -122,000.00 |
| Dec 31, 2024 | -165,000.00 |
| Dec 31, 2024 | -165,000.00 |
| Sep 30, 2024 | -192,000.00 |
| Sep 30, 2024 | -192,000.00 |
| Jun 30, 2024 | -60,000.00 |
| Jun 30, 2024 | -60,000.00 |
| Mar 31, 2024 | -151,000.00 |
| Mar 31, 2024 | -151,000.00 |
| Dec 31, 2023 | -165,000.00 |
| Dec 31, 2023 | -165,000.00 |
| Sep 30, 2023 | -154,000.00 |
| Sep 30, 2023 | -154,000.00 |
| Jun 30, 2023 | -245,000.00 |
| Jun 30, 2023 | -245,000.00 |
| Mar 31, 2023 | -289,000.00 |
| Mar 31, 2023 | -289,000.00 |
| Dec 31, 2022 | -200,000.00 |
| Dec 31, 2022 | -200,000.00 |
| Sep 30, 2022 | -100,000.00 |
| Sep 30, 2022 | -100,000.00 |
| Jun 30, 2022 | -504,000.00 |
| Jun 30, 2022 | -504,000.00 |
| Mar 31, 2022 | -120,000.00 |
| Mar 31, 2022 | -120,000.00 |
| Dec 31, 2021 | -382,000.00 |
| Dec 31, 2021 | -382,000.00 |
| Sep 30, 2021 | -432,000.00 |
| Sep 30, 2021 | -432,000.00 |
| Jun 30, 2021 | -1.53 Mn |
| Jun 30, 2021 | -1.53 Mn |
| Mar 31, 2021 | -262,000.00 |
| Mar 31, 2021 | -262,000.00 |
| Dec 31, 2020 | -94,989.00 |
| Dec 31, 2020 | -94,989.00 |
| Sep 30, 2020 | -12,004.00 |
| Sep 30, 2020 | -12,004.00 |
| Jun 30, 2020 | -7,803.00 |
| Jun 30, 2020 | -7,803.00 |
| Mar 31, 2020 | -5,204.00 |
| Mar 31, 2020 | -5,204.00 |